Biodistribution and in vivo efficacy of genetically modified human mesenchymal stem cells systemically transplanted into a mouse bone fracture model

Archives of Pharmacal Research

Volumn 36, Issue 8, 2013, Pages 1013-1022

  Kang, Jin Wook ^a   Park, Ki Dae ^a   Choi, Youngju ^a   Baek, Dae Hyun ^a   Cho, Wan Seob ^a   Choi, Mina ^a   Park, Jae Hyun ^a   Choi, Kyoung Suk ^a   Kim, Hyung Soo ^a   Yoo, Tae Moo ^a  

^a Korea Food and Drug Administration   (South Korea)

Author keywords

Biodistribution; Human mesenchymal stem cells (hMSCs); In vivo efficacy; Mouse bone fracture model; Runx2

Indexed keywords

GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; LUCIFERASE; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL MIGRATION; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA MODIFICATION; FEMUR FRACTURE; FIBROBLAST; FRACTURE HEALING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMUR; FRACTURES, BONE; GENETIC VECTORS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION;

EID: 84881265430     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0132-4     Document Type: Article

References (29)

1. Barry, F.P.; and J.M. Murphy. 2004. Mesenchymal stem cells: Clinical applications and biological characterization. International Journal of Biochemistry & Cell Biology 36: 568-584.
2. Bostrom, M.P.; K.J. Saleh, and T.A. Einhorn. 1999. Osteoinductive growth factors in preclinical fracture and long bone defects models. Orthopedic Clinics of North America 30: 647-658.
3. Brighton, C.T.; and R.M. Hunt. 1986. Histochemical localization of calcium in the fracture callus with potassium pyroantimonate: Possible role of chondrocyte mitochondrial calcium in callus calcification. Journal of Bone and Joint Surgery 68(5): 703-715.
4. Brighton, C.T.; and R.M. Hunt. 1997. Early histologic and ultrastructural changes in microvessels of periosteal callus. Journal of Orthopaedic Trauma 11(4): 244-253.
5. Bucholz, R.W. 2002. Nonallograft osteoconductive bone graft substitutes. Clinical Orthopaedics and Related Research 395: 44-52.
6. Byers, B.A.; G.K. Pavlath, T.J. Murphy, G. Karsenty, and A.J. Garcia. 2002. Cell-type dependent up-regulation of in vitro mineralization after overexpression of the osteoblast-specific transcription factor Runx2/Cbfal. Journal of Bone and Mineral Research 17: 1931-1944.
7. Chang, J.T.; I.H. Chen, C.T. Liao, H.M. Wang, Y.M. Hsu, K.F. Hung, C.J. Lin, L.L. Hsieh, and A.J. Cheng. 2002. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clinical Biochemistry 35(8): 591-596.
8. Choi, S.T.; J.H. Kim, E.J. Kang, S.W. Lee, M.C. Park, Y.B. Park, and S.K. Lee. 2008. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47: 1775-1779.
9. Chua, C.W.; Y.T. Chiu, H.F. Yuen, K.-W. Chan, K. Man, X. Wang, M.-T. Ling, and Y.-C. Wong. 2009. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: Validating Runx2 as a potential antimetastatic drug screening platform. Clinical Cancer Research 15: 4322-4335.
10. Dalle Carbonare, L.; A. Frigo, G. Francia, M.V. Davì, L. Donatelli, C. Stranieri, P. Brazzarola, M.C. Zatelli, F. Menestrina, and M.T. Valenti. 2012. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer. Journal of Clinical Endocrinology and Metabolism 97: E1249-E1256.
11. Ducy, P.; R. Zhang, V. Geoffroy, I.A.L. Ridal, and G. Karsenty. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
12. Franceschi, R.T.; and G. Xiao. 2003. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. Journal of Cellular Biochemistry 88: 446-454.
13. Franceschi, R.T. 2003. Functional cooperativity between osteoblast transcription factors: Evidence for the importance of subnuclear macromolecular complexes. Calcified Tissue International 72: 638-642.
14. Franceschi, R.T.; S. Yang, R.B. Rutherford, P.H. Krebsbach, M. Zhao, and D. Wang. 2004. Gene Therapy approaches for Bone Regeneration. Cells Tissues Organs 176: 95-108.
15. Gazit, D.; G. Turgeman, P. Kelley, E. Wang, M. Jalenak, Y. Zilberman, and I. Moutsatsos. 1999. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. Journal of Gene Medicine 1: 121-133.
16. Ham, A.W.; and W.R. Harris. 1971. "Repair and transplantation of bone", the biochemistry and physiology of bone, 337-399. New York: Academic Press.
17. Harada, S.; and G.A. Rodan. 2003. Control of osteoblast function and regulation of bone mass. Nature 423: 349-355.
18. Karsenty, G.; P. Ducy, M. Starbuck, M. Priemel, J. Shen, V. Geoffroy, and M. Amling. 1999. Cbfa1 as a regulator of osteoblast differentiation and function. Bone 25: 107-108.
19. Kawai, M.; K. Bessho, S. Kaihara, J. Sonobe, K. Oda, T. Iizuka, and H. Maruyama. 2003. Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. Human Gene Therapy 14: 1547-1556.
20. Kayed, H.; X. Jiang, S. Keleg, R. Jesnowski, T. Giese, M.R. Berger, I. Esposito, M. Löhr, H. Friess, and J. Kleeff. 2007. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. British Journal of Cancer 97: 1106-1115.
21. Kimelman, N.; G. Pelled, G.A. Helm, J. Huard, E.M. Schwarz, and D. Gazit. 2007. Review: Gene- and stem cell-based therapeutics for bone regeneration and repair. Tissue Engineering 13: 1135-1150.
22. Kishimoto, K.N.; Y. Watanabe, H. Nakamura, and S. Kokubun. 2002. Ectopic bone formation by electroporatic transfer of bone morphogenetic protein-4 gene. Bone 31: 340-347.
23. Komori, T.; H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, and T. Kishimoto. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
24. Lee, S.H.; X. Che, J.H. Jeong, J.Y. Choi, Y.J. Lee, Y.H. Lee, S.C. Bae, and Y.M. Lee. 2012. Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. Journal of Biological Chemistry 287: 14760-14771.
25. Phillips, J.E.; C.A. Gersbach, and A.J. Garcia. 2007. Virus-based gene therapy strategies for bone regeneration. Biomaterials 28: 211-229.
26. Pratap, J.; A. Javed, L.R. Languino, A.J. van Wijnen, J.L. Stein, G.S. Stein, and J.B. Lian. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Molecular Cell Biology 25: 8581-8591.
27. Sase, T.; T. Suzuki, K. Miura, K. Shiiba, I. Sato, Y. Nakamura, K. Takagi, Y. Onodera, Y. Miki, M. Watanabe, K. Ishida, S. Ohnuma, H. Sasaki, R. Sato, H. Karasawa, C. Shibata, M. Unno, I. Sasaki, and H. Sasano. 2012. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. International Journal of Cancer 131: 2284-2293.
28. Wheater, P.R.; H.G. Burkit, and V.G. Daniels. 1979. Functional histology: A text and colour atlas. New York: Churchill livingstone Press.
29. Younger, E.M.; and M.W. Chapman. 1989. Morbidity at bone graft donor sites. Journal of Orthopaedic Trauma 3: 192-195.